Version July 2025
| Drug | Mechanism | |
| Immune | Non-immune | |
| Antibiotics | ||
| Rifampin* | ||
| Sulfisoxazole | X | |
| Trimethoprim-sulfamethoxazole | X | |
| Antipsychotics | ||
| Quetiapine | X | |
| Antiseizure medications | ||
| Valproic acid | X | |
| Cancer therapies | ||
| Bevacizumab | X | |
| Bortezomib | X | |
| Carfilzomib | X | |
| Dasatinib | X | |
| Docetaxel | X | |
| Gemcitabine | X | X |
| Imatinib | X | |
| Ixazomib | X | |
| Mitomycin | X | |
| Oxaliplatin | X | |
| Palbociclib | X | |
| Pentostatin | X | |
| Ponatinib | X | |
| Sunitinib | X | |
| Vincristine | X | |
| Illicit drugs | ||
| Cocaine | X | |
| Oxycodone (OxyContin formulated with PEO) | X | |
| MDMA (Ecstasy) | X | |
| Gene therapy | ||
| Onasemnogene abeparvovec* | ||
| Hemophilia A | ||
| Emicizumab | X | |
| Immunosuppressive therapies | ||
| Adalimumab | X | |
| Cyclosporine | X | |
| Everolimus | X | |
| Infliximab | X | |
| Interferons (type 1, alpha and beta) | X | |
| Intravenous immune globulin (IVIG) | X | |
| Sirolimus | X | |
| Tacrolimus | X | |
| Leg cramps, other minor symptoms, malaria (also as a beverage: tonic water, bitter lemon) | ||
| Quinine | X | |
The listed drugs are those that have been reported to have definite (≥1 report) or probable (≥2 reports) evidence for a causal association with DITMA. Published reports often described these syndromes as TTP or HUS. Case reports may be available for other drugs.
For some illicit drugs, DITMA occurred when the oral formulation was used by injection.
Some drugs that have been commonly reported to be associated with DITMA, such as clopidogrel, do not describe evidence supporting a definite or probable causal association.
The presentation and prognosis differ between immune-mediated and toxicity-mediated DITMA.
Refer to UpToDate topics on DITMA for details of evaluation and management.
DITMA: drug-induced thrombotic microangiopathy; HUS: hemolytic uremic syndrome; MDMA: 3,4-methylenedioxymethamphetamine; PEO: polyethylene oxide; TMA: thrombotic microangiopathy; TTP: thrombotic thrombocytopenic purpura.
* For rifampin, supporting evidence is lacking; for rifampin and onasemnogene abeparvovec, the proposed mechanism (immune versus non-immune) is unknown.
